Search

Your search keyword '"Hashikata, Takehiro"' showing total 41 results
Start Over Author "Hashikata, Takehiro"
41 results on '"Hashikata, Takehiro"'

4. Impact of Diastolic Vessel Restriction on Quality of Life in Symptomatic Myocardial Bridging Patients Treated With Surgical Unroofing: Preoperative Assessments With Intravascular Ultrasound and Coronary Computed Tomography Angiography

Author

Hashikata, Takehiro, Honda, Yasuhiro, Wang, Hanjay, Pargaonkar, Vedant S., Nishi, Takeshi, Hollak, M. Brooke, Rogers, Ian S., Nieman, Koen, Yock, Paul G., Fitzgerald, Peter J., Schnittger, Ingela, Boyd, Jack H., and Tremmel, Jennifer A.

Published
2021
Full Text
View/download PDF

20. Empagliflozin attenuates neointimal hyperplasia after drug-eluting-stent implantation in patients with type 2 diabetes

Author

Hashikata, Takehiro, primary, Ikutomi, Masayasu, additional, Jimba, Takahiro, additional, Shindo, Akito, additional, Kakuda, Nobutaka, additional, Katsushika, Susumu, additional, Yokoyama, Masaaki, additional, Kishi, Mikio, additional, Sato, Takahiro, additional, Matsushita, Masashiro, additional, Ohnishi, Satoshi, additional, and Yamasaki, Masao, additional

Published
2020
Full Text
View/download PDF

22. Postprandial hyperglycemia and endothelial function in type 2 diabetes: focus on mitiglinide

Author

Kitasato Lisa, Tojo Taiki, Hatakeyama Yuko, Kameda Ryo, Hashikata Takehiro, and Yamaoka-Tojo Minako

Subjects
Atherosclerosis, Endothelial function, Cardiovascular disease prevention, Diseases of the circulatory (Cardiovascular) system, RC666-701
Abstract

Abstract The risk of cardiovascular complication in a diabetes patient is similar to that in a nondiabetic patient with a history of myocardial infarction. Although intensive control of glycemia achieved by conventional antidiabetic agents decreases microvascular complications such as retinopathy and nephropathy, no marked effect has been reported on macrovascular complications or all-cause mortality. Evidence from VADT, ACCORD, and ADVANCE would suggest that glycemic control has little effect on macrovascular outcomes. Moreover, in the case of ACCORD, intensive glycemic control may be associated with an increased risk of mortality. There is sufficient evidence that suggests that postprandial hyperglycemia may be an independent risk factor for cardiovascular disease in diabetes patients. However, there are no prospective clinical trials supporting the recommendation that lowering postprandial blood glucose leads to lower risk of cardiovascular outcomes. Mitiglinide is a short-acting insulinotropic agent used in type 2 diabetes treatment. It has a rapid stimulatory effect on insulin secretion and reduces postprandial plasma glucose level in patients with type 2 diabetes. Because of its short action time, it is unlikely to exert adverse effects related to hypoglycemia early in the morning and between meals. Mitiglinide reduces excess oxidative stress and inflammation, plays a cardioprotective role, and improves postprandial metabolic disorders. Moreover, mitiglinide add-on therapy with pioglitazone favorably affects the vascular endothelial function in type 2 diabetes patients. These data suggest that mitiglinide plays a potentially beneficial role in the improvement of postprandial hyperglycemia in type 2 diabetes patients and can be used to prevent cardiovascular diseases. Although the results of long-term, randomized, placebo-controlled trials for determining the cardiovascular effects of mitiglinide on clinical outcomes are awaited, this review is aimed at summarizing substantial insights into this topic.

Published
2012
Full Text
View/download PDF

23. Linagliptin Suppresses Electrical and Structural Remodeling in the Isoproterenol Induced Myocardial Injury Model

Author

Ishizue, Naruya, primary, Niwano, Shinichi, additional, Niwano, Hiroe, additional, Oikawa, Jun, additional, Nakamura, Hironori, additional, Hashikata, Takehiro, additional, Igarashi, Tazuru, additional, Fujiishi, Tamami, additional, Yoshizawa, Tomoharu, additional, Kishihara, Jun, additional, Satoh, Akira, additional, Fukaya, Hidehira, additional, and Ako, Junya, additional

Published
2019
Full Text
View/download PDF

26. Lower Level of Low Density Lipoprotein Cholesterol is Associated with a Higher Increase in the Fractional Flow Reserve in Patients with Fixed-dose Rosuvastatin

Author

Hashikata, Takehiro, primary, Tojo, Taiki, additional, Muramatsu, Yusuke, additional, Sato, Toshimitsu, additional, Kakizaki, Ryota, additional, Nemoto, Teruyoshi, additional, Fujiyoshi, Kazuhiro, additional, Namba, Sayaka, additional, Kitasato, Lisa, additional, Hashimoto, Takuya, additional, Kameda, Ryo, additional, Shimohama, Takao, additional, Yamaoka-Tojo, Minako, additional, and Ako, Junya, additional

Published
2018
Full Text
View/download PDF

28. STENT EDGE STRUT ON NORMAL SEGMENT IS LESS COVERED IN EARLY PHASE AFTER DRUG ELUTING STENT IMPLANTATION

Author

Kakizaki, Ryota, primary, Minami, Yoshiyasu, additional, Hashikata, Takehiro, additional, Nemoto, Teruyoshi, additional, Fujiyoshi, Kazuhiro, additional, Namba, Sayaka, additional, Hashimoto, Takuya, additional, Yanagisawa, Tomoyoshi, additional, Meguro, Kentaro, additional, Shimohama, Takao, additional, Tojo, Taiki, additional, and Ako, Junya, additional

Published
2017
Full Text
View/download PDF

31. Ezetimibe enhances and stabilizes anticoagulant effect of warfarin

Author

Hashikata, Takehiro, primary, Yamaoka-Tojo, Minako, additional, Kakizaki, Ryota, additional, Nemoto, Teruyoshi, additional, Fujiyoshi, Kazuhiro, additional, Namba, Sayaka, additional, Kitasato, Lisa, additional, Hashimoto, Takuya, additional, Ishii, Shunsuke, additional, Kameda, Ryo, additional, Shimohama, Takao, additional, Tojo, Taiki, additional, and Ako, Junya, additional

Published
2016
Full Text
View/download PDF

32. Teneligliptin improves left ventricular diastolic function and endothelial function in patients with diabetes

Author

Hashikata, Takehiro, primary, Yamaoka-Tojo, Minako, additional, Kakizaki, Ryota, additional, Nemoto, Teruyoshi, additional, Fujiyoshi, Kazuhiro, additional, Namba, Sayaka, additional, Kitasato, Lisa, additional, Hashimoto, Takuya, additional, Kameda, Ryo, additional, Maekawa, Emi, additional, Shimohama, Takao, additional, Tojo, Taiki, additional, and Ako, Junya, additional

Published
2015
Full Text
View/download PDF

39. Abstract 10349: Preventive Effect of Empagliflozin on Neointimal Hyperplasia After Drug Eluting Stent Implantation in Patients With Type2 Diabetes

Author

Hashikata, Takehiro, Kishi, Mikio, Ikutomi, Masayasu, Jimba, Takahiro, Matsushita, Masashirou, Shindo, Akito, Katsushika, Susumu, Sato, Takahiro, Ohnishi, Satoshi, Yamasaki, Masao, and Kakuda, Nobutaka

Abstract

Introduction:The effects of sodium-glucose co-transporter 2 inhibitor (SGLT2i) after drug eluting stent (DES) implantation remains unknown. Here, we evaluated whether empagliflozin, a SGLT2i, affects neointimal condition in patients with type 2 diabetes who received DES implantation.Methods:Uncontrolled diabetic patients with coronary disease planned for DES stenting were consecutively enrolled. The patients were randomly assigned to receive empagliflozin in addition to standard therapy or intensive therapy using other glucose-lowering drugs (oGLD). Bioresorbable-polymer DESs (Ultimaster or Synergy stent) were used in all cases. Optical coherence tomography (OCT) was performed at 12 months to assess the neointimal reaction after DES placement.Results:A total of 30 patients (33 lesions) were analyzed (n=16 in empagliflozin group, n=14 in oGLD group). The levels of hemoglobin A1c were not significantly different between the groups both at baseline [8.3 ? 1.3 vs 8.1 ? 0.5%, P = 0.73] and follow-up [7.2 ? 0.8 vs 7.3 ? 0.9%, P = 0.46]. In OCT analysis, neointima was significantly less in empagliflozin group than oGLT group (neointimal volume: 1.19 ? 0.29 vs 1.48 ? 0.27 mm3/mm, P = 0.02, maximal neointimal thickness: 247 ? 49 vs 295 ? 34 ?m, P = 0.01), although the other standard variables were equivalent (P > 0.05 for each). No significant between-group difference was shown in the ratio of neointimal coverage and malapposed stent strut. In addition, neointimal volume was positively correlated with changes of BMI as well as systolic and diastolic blood pressure, whereas no correlation was seen in the other parameters including changes of blood glucose.Conclusions:In patients with type 2 diabetes, empagliflozin plus standard therapy reduced neointimal progression as compared with oGLD at 12 months after DES implantation. Our data possibly support a beneficial effect of empagliflozin in type2 diabetes required for coronary revascularization therapy.

Published
2019
Full Text
View/download PDF

40. IMPACT OF MYOCARDIAL BRIDGING ON CORONARY ARTERY PLAQUE FORMATION AFTER HEART TRANSPLANTATION: SERIAL IVUS ANALYSIS WITH NEAR-INFRARED SPECTROSCOPY.

Author

Yoshida, Akihiro, Saito, Kan, Kashiyama, Kuninobu, Hashikata, Takehiro, SAKAGAMI, AZUSA, Nishi, Takeshi, Kim, Juka S., Assi, Abdul Elah, Yock, Paul G., Yeung, Alan C., Fitzgerald, Peter J., Khush, Kiran, Fearon, William Fuller, Parikh, Rushi, and Honda, Yasuhiro

Subjects
*NEAR infrared spectroscopy, *HEART transplantation, *CORONARY arteries
Published
2024
Full Text
View/download PDF

41. Repetitive restenosis in a biodegradable polymer sirolimus-eluting stent with hypersensitivity reaction: a case report.

Author

Jimba T, Hashikata T, Matsushita M, and Yamasaki M

Abstract

Background: Hypersensitivity reaction is a classic cause of in-stent restenosis (ISR) in coronary stents, typically reported in bare-metal stents and first-generation drug-eluting stents. Biodegradable polymer sirolimus-eluting stent (BP-SES) was developed with the concept of biocompatibility, and there has been no report of ISR of BP-SES with hypersensitivity reaction., Case Summary: An 81-year-old woman presented with ST-elevation acute inferior myocardial infarction. Primary percutaneous coronary intervention was performed for the culprit lesion in the left circumflex artery with a permanent polymer everolimus-eluting stent (PP-EES), followed by BP-SES implantation in the left anterior descending artery. Eight months later, coronary angiography showed total occlusion of the PP-EES and diffuse ISR in the BP-SES, treated with a paclitaxel-eluting balloon. Fluorodeoxyglucose with positron emission tomography showed increased uptake around the BP-SES, and cardiac magnetic resonance imaging revealed a late gadolinium-enhanced area around both stents. Four months later, she developed re-ISR in the BP-SES, and optical coherence tomography demonstrated diffuse-layered neointimal hyperplasia with microvascularization and peri-strut low-intensity area. She was successfully treated with coronary artery bypass grafting., Discussion: Our case demonstrated repetitive short-term ISR of the BP-SES. Observation by both intravascular and non-invasive imaging modalities suggested the presence of hypersensitivity reaction localized in the stent. Hypersensitivity to the metal may be a possible mechanism because both stents are composed of L605 cobalt-chromium alloy. This is the first report of ISR of a BP-SES with hypersensitivity reaction. Non-invasive imaging can be useful to assess this critical condition., (© The Author(s) 2020. Published by Oxford University Press on behalf of the European Society of Cardiology.)

Published
2020
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results